Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04315701
Title A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Southern California
Indications

skin squamous cell carcinoma

Therapies

Cemiplimab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.